登录 | 注册    关注公众号  
微信公众号
搜索
 > 【IL-2 R alpha】

IL-2 R alpha信息

英文名称:Interleukin-2 receptor alpha chain
中文名称:白细胞介素-2受体α链
靶点别称:TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,Insulin-Dependent Diabetes Mellitus 10,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,Interleukin-2 Receptor alpha Subunit,IL-2R alpha
上市药物数量:3
临床药物数量:16
最高研发阶段:批准上市

抗体项目交易平台

项目名称 项目阶段 分子类型 分子来源 疾病领域 适应症
CD25 mAb - 01 PCC 单抗 鼠源人源化 实体瘤 泛肿瘤

IL-2 R alpha分子别名

IL2RA,CD25,p55,IL2-RA,IL-2-RA

IL-2 R alpha分子背景

Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

IL-2 R alpha上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

IL-2 R alpha临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定